Automatic External Defibrillation Monitoring in Cardiac Arrest

This study has been completed.
Sponsor:
Collaborator:
Emory University
Information provided by (Responsible Party):
A. Maziar Zafari, Atlanta VA Medical Center
ClinicalTrials.gov Identifier:
NCT00382928
First received: September 29, 2006
Last updated: June 30, 2014
Last verified: May 2014
  Purpose

We propose to randomize automatic external cardioverter/defibrillators (AECD) in patients who are at high risk for life-threatening abnormal heart rhythms (arrhythmias) and are admitted to the telemetry ward, all other treatments being constant including cardiopulmonary resuscitation.

We hypothesize that the automatic, rapid, accurate and specific diagnostic and therapeutic technology used in AECDs will further increase the rate of survival in patients with cardiac arrest through rapid and automatic defibrillation, independent of operator initiation, as compared to standard cardiopulmonary resuscitation initiated by healthcare providers.


Condition Intervention Phase
Death, Sudden, Cardiac
Ventricular Fibrillation
Tachycardia, Ventricular
Device: Defibrillation of pulseless VT/VF by AECD
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Automatic External Defibrillation Monitoring in Cardiac Arrest

Resource links provided by NLM:


Further study details as provided by Atlanta Research and Education Foundation:

Primary Outcome Measures:
  • Number of Participants Without Defibrillation [ Time Frame: 10 minutes ] [ Designated as safety issue: No ]
    Time to defibrillation: interval between onset of VT/VF and delivery of first shock. Expected time to defibrillation for AECD group: 30±30 seconds; expected time to defibrillation for Standard of Care group: 180±180.


Secondary Outcome Measures:
  • Frequency of Abnormal Rhythms Monitored by the AECD [ Time Frame: During the duration of hospital admission on the telemetry ward. ] [ Designated as safety issue: No ]
  • Survival to Discharge [ Time Frame: At discharge ] [ Designated as safety issue: No ]
  • Cerebral Performance at Discharge [ Time Frame: At discharge ] [ Designated as safety issue: No ]

    Cerebral Performance Categories/CPC scale:

    CPC 1: Good cerebral performance - conscious, alert, able to work, might have mild neurologic or psychological deficit.

    CPC 2: Moderate cerebral disability - conscious, sufficient cerebral function for independent activities of daily life. Able to work in sheltered environment.

    CPC 3: Severe cerebral disability - conscious, dependent on others for daily support because of impaired brain function. Ranges from ambulatory state to severe dementia or paralysis.

    CPC 4: Coma or vegetative state - any degree of coma without the presence of all brain death criteria. Unawareness, even if appears awake (vegetative state) without interaction with environment; may have spontaneous eye opening and sleep/awake cycles. Cerebral unresponsiveness.

    CPC 5: Brain death - apnea, areflexia, electroencephalogram (EEG) silence, etc.



Enrollment: 192
Study Start Date: October 2006
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Standard of Care Group
Patients will receive standard of care measures in case of cardiac arrest. They will not receive AECD monitoring or intervention
Experimental: AECD Monitoring + Standard of Care Group
Patients will receive AECD monitoring and intervention in addition to standard of care in case of cardiac arrest during admission to the hospital. Defibrillation of pulseless VT/VF by AECD.
Device: Defibrillation of pulseless VT/VF by AECD
In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.

Detailed Description:

Cardiac arrest (CA) is defined as the sudden cessation of effective cardiac pumping function as a result of either ventricular asystole (inactivity of the heart) or pulseless ventricular tachycardia/ventricular fibrillation (VT/VF). Pulseless ventricular tachycardia/ventricular fibrillation is an abnormal electrical activity of the ventricles of the heart. Rapid diagnosis and treatment are essential because first, more than a few minutes of total CA results in permanent damage to the brain due to lack of oxygen, and second, the success of resuscitative measures is related to the rapidity with which they are instituted following arrest. For a person in VT/VF the probability of successful defibrillation and subsequent survival to hospital discharge is directly and negatively related to the interval between onset of VT/VF and delivery of first shock.

Comparison: By using AECDs we will evaluate if an automatic, rapid, accurate and specific diagnostic technology will further increase the rate of survival in patients with VT/VF by rapid and automatic defibrillation, independent of operator initiation, as compared to standard cardiopulmonary resuscitation (CPR) with conventional defibrillators initiated by healthcare providers. This trial will be a randomized, controlled trial and will test if AECDs can improve outcome measures when compared to traditional responses.

Conventional defibrillators are manually operated defibrillators that have to be attached to the patient and operated by a healthcare provider or layperson. In contrast, the purpose of AECDs is to automatically detect life-threatening arrhythmias and deliver external shocks according to a programmable prescription for hospitalized patients, who may be at transient risk for the development of life-threatening arrhythmias. AECDs immediately and automatically monitor, detect and treat cardiac arrhythmias with no human intervention. The AECD proposed to be utilized in this trial, PowerHeart CRM, a product of Cardiac Science, Inc, has been evaluated in the hospital setting to assess safety and efficacy, and has been approved by the FDA to be prophylactically attached to hospital patients and provide automatic defibrillation therapy without human intervention.

All patients admitted to the telemetry unit will be asked to volunteer for this study. Up to 3,000 patients will be asked to volunteer in this study during their stay in the telemetry unit. This study will evaluate if there is a way to improve survival in CA by comparing two groups

Group 1: This group includes patients admitted to telemetry unit who will undergo standard measures of CPR in case cardiac arrest is suspected.

Group 2: This group includes patients admitted to telemetry unit who will have an AECD attached to the chest wall and who will also undergo standard measures of CPR in case of cardiac arrest.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients admitted to telemetry ward and emergency department
  • Age > 18 years.

Exclusion Criteria:

  • Pregnant women
  • Patients with R wave less than 0.5 millivolts.
  • Patients with functioning Internal Cardiac Device.
  • Patients with cardiac pacemakers if oversensing by AECD is demonstrated (double counting of pacer spikes).
  • Patients with visible chest lesions that would prevent AECD pad placement.
  • Patients who are designated Do Not Resuscitate.
  • Right bundle branch block.
  • Patients with Parkinson's disease.
  • Patients with seizure disorders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00382928

Locations
United States, Georgia
Atlanta Veterans Adminstration Medical Center
Decatur, Georgia, United States, 30033
Sponsors and Collaborators
Atlanta Research and Education Foundation
Emory University
Investigators
Principal Investigator: A. Maziar Zafari, M.D., Ph.D Division of Cardiology, Atlanta Veterans Adminstration Medical Center/ Emory University, Decatur, GA
  More Information

Additional Information:
No publications provided

Responsible Party: A. Maziar Zafari, Chief, Cardiology, Atlanta VA Medical Center
ClinicalTrials.gov Identifier: NCT00382928     History of Changes
Other Study ID Numbers: 1216-2004
Study First Received: September 29, 2006
Results First Received: December 12, 2013
Last Updated: June 30, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Atlanta Research and Education Foundation:
Randomized Controlled Trials
Defibrillators
Medical Devices

Additional relevant MeSH terms:
Death, Sudden
Death, Sudden, Cardiac
Heart Arrest
Tachycardia
Tachycardia, Ventricular
Ventricular Fibrillation
Arrhythmias, Cardiac
Cardiovascular Diseases
Death
Heart Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on October 21, 2014